Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
106 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Diabetic Neuropathy - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy - Pipeline Review, H1 2017, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape. Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. The predisposing factors are obesity, hypertension, high lipid and sugar levels, smoking, etc. It may be managed by medication and dietary modification. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Neuropathy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 3, 16 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively. Diabetic Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders). - The pipeline guide reviews pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Diabetic Neuropathy - Overview Diabetic Neuropathy - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Diabetic Neuropathy - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Diabetic Neuropathy - Companies Involved in Therapeutics Development Achelios Therapeutics Inc Angelini Group Apollo Endosurgery Inc Araim Pharmaceuticals Inc Celgene Corp Commence Bio Inc Grunenthal GmbH Kineta Inc KPI Therapeutics Inc Medifron DBT Co Ltd Neuralstem Inc NovaLead Pharma Pvt Ltd Omeros Corp Reata Pharmaceuticals Inc Relief Therapeutics Holding AG ViroMed Co Ltd Diabetic Neuropathy - Drug Profiles A-100 - Drug Profile Product Description Mechanism Of Action R&D Progress AAD-2004 - Drug Profile Product Description Mechanism Of Action R&D Progress atexakin alfa - Drug Profile Product Description Mechanism Of Action R&D Progress BNV-222 - Drug Profile Product Description Mechanism Of Action R&D Progress cibinetide - Drug Profile Product Description Mechanism Of Action R&D Progress CMB-200 - Drug Profile Product Description Mechanism Of Action R&D Progress CNV-2197944 - Drug Profile Product Description Mechanism Of Action R&D Progress Cyndacel-M - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury - Drug Profile Product Description Mechanism Of Action R&D Progress KCP-400 - Drug Profile Product Description Mechanism Of Action R&D Progress ketoprofen - Drug Profile Product Description Mechanism Of Action R&D Progress KU-32 - Drug Profile Product Description Mechanism Of Action R&D Progress Lpathomab - Drug Profile Product Description Mechanism Of Action R&D Progress MDR-16523 - Drug Profile Product Description Mechanism Of Action R&D Progress MDR-652 - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis - Drug Profile Product Description Mechanism Of Action R&D Progress NLP-198 - Drug Profile Product Description Mechanism Of Action R&D Progress NSI-189 - Drug Profile Product Description Mechanism Of Action R&D Progress NSI-566 - Drug Profile Product Description Mechanism Of Action R&D Progress OMS-721 - Drug Profile Product Description Mechanism Of Action R&D Progress PDA-002 - Drug Profile Product Description Mechanism Of Action R&D Progress Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Male Health - Drug Profile Product Description Mechanism Of Action R&D Progress pirenzepine hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress RTA-901 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Diabetic Neuropathy - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Pain - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Hsp90 for Peripheral Neuropathy and Neurodegenerative Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress trazodone hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress U-2902 - Drug Profile Product Description Mechanism Of Action R&D Progress VM-202 - Drug Profile Product Description Mechanism Of Action R&D Progress XK-568b - Drug Profile Product Description Mechanism Of Action R&D Progress Diabetic Neuropathy - Dormant Projects Diabetic Neuropathy - Discontinued Products Diabetic Neuropathy - Product Development Milestones Featured News & Press Releases Sep 08, 2016: ViroMed proceeding with the World's first phase III gene therapy clinical trial for diabetic peripheral neuropathy Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab Mar 18, 2011: ViroMed Enrolls Final Patient For US VM202-DPN Phase I/II Clinical Trial Mar 04, 2009: ViroMed Receives Approval from US FDA for Phase I/II Trial for Diabetic Neuropathy Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Diabetic Neuropathy, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Diabetic Neuropathy - Pipeline by Achelios Therapeutics Inc, H1 2017 Diabetic Neuropathy - Pipeline by Angelini Group, H1 2017 Diabetic Neuropathy - Pipeline by Apollo Endosurgery Inc, H1 2017 Diabetic Neuropathy - Pipeline by Araim Pharmaceuticals Inc, H1 2017 Diabetic Neuropathy - Pipeline by Celgene Corp, H1 2017 Diabetic Neuropathy - Pipeline by Commence Bio Inc, H1 2017 Diabetic Neuropathy - Pipeline by Grunenthal GmbH, H1 2017 Diabetic Neuropathy - Pipeline by Kineta Inc, H1 2017 Diabetic Neuropathy - Pipeline by KPI Therapeutics Inc, H1 2017 Diabetic Neuropathy - Pipeline by Medifron DBT Co Ltd, H1 2017 Diabetic Neuropathy - Pipeline by Neuralstem Inc, H1 2017 Diabetic Neuropathy - Pipeline by NovaLead Pharma Pvt Ltd, H1 2017 Diabetic Neuropathy - Pipeline by Omeros Corp, H1 2017 Diabetic Neuropathy - Pipeline by Reata Pharmaceuticals Inc, H1 2017 Diabetic Neuropathy - Pipeline by Relief Therapeutics Holding AG, H1 2017 Diabetic Neuropathy - Pipeline by ViroMed Co Ltd, H1 2017 Diabetic Neuropathy - Dormant Projects, H1 2017 Diabetic Neuropathy - Dormant Projects, H1 2017 (Contd..1), H1 2017 Diabetic Neuropathy - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
